Oxaprotiline

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Oxaprotiline
Accession Number
DB09307
Type
Small Molecule
Groups
Experimental
Description

Oxaprotiline is a norepinephrine reuptake inhibitor of the tetracyclic antidepressant family that is related to maprotiline. Though investigated as an antidepressant, it was never marketed. Oxaprotiline is a racemic compound composed of two isomers, R(−)- or levo- oxaprotiline (levoprotiline; CGP-12,103-A), and S(+)- or dextro- oxaprotiline (dextroprotiline; CGP-12,104-A). Both enantiomers are active, with the levo- form acting merely as an antihistamine and the dextro- form having a more expansive pharmacology, but with both unexpectedly still retaining antidepressant effects.

Synonyms
  • Hydroxymaprotiline
Categories
UNII
3V3Z2HK4LS
CAS number
56433-44-4
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for the treatment of depression.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with (S)-Warfarin.
2,4-thiazolidinedioneOxaprotiline may decrease the hypoglycemic activities of 2,4-thiazolidinedione.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of serotonin syndrome can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Oxaprotiline.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of serotonin syndrome can be increased when Oxaprotiline is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineThe risk or severity of serotonin syndrome can be increased when 3,4-Methylenedioxyamphetamine is combined with Oxaprotiline.
3,5-diiodothyropropionic acidThe risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when 3,5-diiodothyropropionic acid is combined with Oxaprotiline.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of serotonin syndrome can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Oxaprotiline.
4-hydroxycoumarinThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with 4-hydroxycoumarin.
4-MethoxyamphetamineOxaprotiline may increase the vasopressor activities of 4-Methoxyamphetamine.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910433
Wikipedia
Oxaprotiline

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on November 12, 2015 09:25 / Updated on November 02, 2018 07:01